A Participant-Level Integrative Data Analysis of Differential Placebo Response for Suicidal Ideation and Nonsuicidal Depressive Symptoms in Clinical Trials of Intravenous Racemic Ketamine
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Background: Clinical trials of intravenous (IV) racemic (R,S)-ketamine (hereafter referred to as IV ketamine) have consistently reported rapid and substantial reductions in overall depressive symptoms compared with saline (inactive placebo) or midazolam (active placebo). The evidence for IV ketamine’s specific effects on suicidal ideation is less clear, however. This study sought to examine whether differential placebo (saline or midazolam) response to overall depressive symptoms vs suicidal ideation may help explain these divergent findings. Methods: Data for this participant-level integrative data analysis were drawn from 151 participants across 10 studies, and linear regression was used to examine the relationship between placebo response for suicidal ideation vs other depressive symptoms indexed from standard rating scales—specifically, depressed mood, anhedonia, anxiety, and guilt—over time. Results: For participants receiving saline placebo (n = 46), greater placebo response was observed for suicidal ideation compared with other symptoms indexed from standard depression rating scales, except for anxiety. For those receiving midazolam placebo (n = 105), greater placebo response was observed for suicidal ideation compared with depressed mood or anhedonia, and no significant differences were observed when comparing suicidal ideation with anxiety or guilt. Conclusions: Taken together, the results provide preliminary evidence of a differential placebo response for suicidal ideation vs other depressive symptoms, while anxiety and suicidal ideation appear to produce similar placebo response profiles. These findings may help explain the more modest findings in clinical IV ketamine trials for suicidal ideation than overall depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, it should be noted that a recent systematic review found that intranasal esketamine did not perform better than placebo at reducing suicidal ideation [90], though this finding may have been confounded by the high placebo response rate that exists when assessing suicidal ideation [91].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [91]
Experimental — accuracy not yet measuredIn the citing paper
“Indeed, previous studies suggest that SI is variable across the day (Kleiman et al., 2017) and may be particularly reactive to the placebo effect (Bloomfield-Clagett et al., 2022).”
From Clinical indicators of the suicide crisis and response to ketamine (2025) · cites this paper as Bloomfield-Clagett et al., 2022
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationPsychosomatic medicine in Germany: more timely than ever
Zipfel, S., Herzog, W., Kruse, J., & Henningsen, P. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000447701 · Cited by 2,323
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Self-citationDiazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationKleiman, E. M., Turner, B. J., Fedor, S., Beale, E. E., Huffman, J. C., & Nock, M. K. (2017) · Journal of Abnormal Psychology · doi:10.1037/abn0000273 · Cited by 831
Sareen, J., Cox, B. J., Afifi, T. O., de Graaf, R., Asmundson, G. J. G., ten Have, M., & Stein, M. B. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.11.1249 · Cited by 824
Zarate, C. A., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N., Cravchik, A., Selter, J., Marquardt, C. A., Liberty, V., & Luckenbaugh, D. A. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.12.010 · Cited by 811
Self-citationWilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Self-citation
Cited by
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“However, it should be noted that a recent systematic review found that intranasal esketamine did not perform better than placebo at reducing suicidal ideation [90], though this fi nding may have been confounded by the high placebo response rate that exists when assessing suicidal ideation [91].”
BackgroundSelf-citationA pilot randomized controlled trial of ketamine in Borderline Personality Disorder
Fineberg, S. K., Choi, E. Y., Shapiro-Thompson, R., Dhaliwal, K., Neustadter, E. S., Sakheim, M., Null, K. E., Diaz, D. T., Rondeau, J. A., Pittaro, G. F., et al. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01540-4 · Cited by 45
Li, W., Chen, L., Su, T., Li, C., Lin, W., Wu, H.-J., Tsai, S., Bai, Y., Tu, P., & Chen, M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.05.024 · Cited by 12
Chen, M., Su, T., Chen, L., Li, C., Wu, H.-J., Lin, W., Tsai, S., Bai, Y., Mao, W., Tu, P., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.03.010 · Cited by 10
Psychedelic therapeutics in psychiatric conditions
Harvey, P. D., & Nemeroff, C. B. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02335-z · Cited by 8
Clinical indicators of the suicide crisis and response to ketamine
Ballard, E. D., Neely, L., Waldman, L., Greenstein, D., & Zarate, C. A. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.11.080 · Cited by 5
Self-citationNeurophysiological biomarkers of treatment response in suicidal ideation: a systematic review
Stapper, N., Benster, L. L., Menon, S., Boyd, E. C., Poorganji, M., Hadas, I., Sun, Y., Appelbaum, L. G., Daskalakis, Z. J., & Weissman, C. R. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03477-2 · Cited by 4
DEPRESSÃO E SEUS DIVERSOS FATORES: UMA ANÁLISE INTEGRADA
LIMA, R. K. A., LIMA, R. K. A., SANTOS, I. C. S., Filho, H. N. F., ARAÚJO, M. S. D., MACÊDO, C. H. S. D., LIMA, E. M., LIMA, L. B., Appio;, P. R., CARATE, C. K., et al. (2023) · doi:10.59290/978-65-6029-058-7.1
Weissman, C. R. (2024) · TSpace (University of Toronto)
Metadata
- Authors
- Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., & Zarate, C. A.
- Affiliations
- National Institutes of Health (US)
- Yale University (US)
- Columbia University Irving Medical Center (US)
- Icahn School of Medicine at Mount Sinai (US)
- Baylor College of Medicine (US)
- University of Ottawa (CA)
- Department of Psychiatry, Massachusetts General Hospital , Boston , USA
- Corresponding author
- Ballard, Elizabeth D
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-08-22
- Volume
- 25
- Issue
- 10
- Pages
- 827-838
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC9593215
- OpenAlex
- W4292664328
- Cited by
- 8
- References
- 40
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 5
- FWCI
- 1.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- public-domain
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, public-domain)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- National Institute of Mental Health (IRP-NIMH-NIH)
- National Institutes of Health (ZIAMH002857)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- intravenous ketamine, racemic ketamine, suicidal ideation, placebo response, saline placebo, depressive mood, anhedonia, anxiety, guilt, depression rating scales
- MeSH terms
- Data Analysis, Depression, Major Depressive Disorder, Humans, Ketamine, Midazolam, Psychiatric Status Rating Scales, Placebo Effect, Suicidal Ideation, Anhedonia
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.